Announcements Trials

Browse Landscape

Phase

Status

Unknown 15 Completed 5 Recruiting 4 Withdrawn 1 Terminated 1 Suspended 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 Gastrointestinal 1

Conditions

Osteosarcoma 1 Drug-Related Side Effects and Adverse Reactions 1

Interventions

Specimen Handling 3 trastuzumab deruxtecan 1 tivozanib 1 pembrolizumab 1 pegamotecan 1 fludarabine phosphate 1 envafolimab 1 cemiplimab 1 atezolizumab 1 apatinib 1 aldesleukin 1 X-Rays 1 Vincristine 1 Vaccines 1 Temozolomide 1 Surgical Procedures, Operative 1 Radiotherapy, Intensity-Modulated 1 Radiotherapy, Image-Guided 1 RFB4(dsFv)-PE38 recombinant immunotoxin 1 Nanoparticles 1 Magnetic Resonance Spectroscopy 1 Health Care Economics and Organizations 1 HMPL-013 1 Everolimus 1 Cyclophosphamide 1 Biopsy 1 Biomarkers 1 Antibodies, Monoclonal 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Suspended × apatinib × Sarcoma × Clear all

NCT04824352 2024-05-14

AIEO

Peking University People's Hospital

Phase 2 Suspended

Osteosarcoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon ⚡